Search results
Results from the WOW.Com Content Network
Current Cancer Drug Targets is a peer-reviewed medical journal published by Bentham Science Publishers.The editor-in-chief is Ruiwen Zhang (UH Drug Discovery Institute). The journal covers research on contemporary molecular drug targets involved in cancer, including medicinal chemistry, pharmacology, molecular biology, genomics, and biochemistry.
The targets and drugs in TTD cover 583 protein biochemical classes and 958 drug therapeutic classes, respectively. [1] The latest version of the International Classification of Diseases (ICD-11) codes released by WHO are incorporated in TTD to facilitate the clear definition of disease/disease class.
Drug Discovery Today is a monthly peer-reviewed scientific journal that is published by Elsevier.It was established in 1996 and publishes reviews on all aspects of preclinical drug discovery from target identification and validation through hit identification, lead identification and optimisation, to candidate selection.
Drug Target Insights is a peer-reviewed open access academic journal focusing on drug treatment targets and clinical therapeutics. The journal was founded in 2006 by Monica Milani and is currently edited by Giulio Zuanetti .
Potential drug targets are not necessarily disease causing but must by definition be disease modifying. [8] An alternative means of identifying new drug targets is forward pharmacology based on phenotypic screening to identify "orphan" ligands [9] whose targets are subsequently identified through target deconvolution. [10] [11] [12]
move to sidebar hide. From Wikipedia, the free encyclopedia
Journal of Drug Targeting is a peer-reviewed medical journal published by Informa that covers research on all aspects of drug delivery and drug targeting for molecular and macromolecular drugs. The editor in chief is Saghir Akhtar (College of Medicine, Qatar University ).
This version contained 1424 approved small molecule drugs and 132 biotech drugs as well as >4000 unique drug targets. Version 3.0 also included drug transporter data, drug pathway data, drug pricing, patent and manufacturing data as well as data on >5000 experimental drugs.